SRH Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

SRH Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-550	Closed	-$18K	–	247
2017 Q2	$18K	Hold	550	–	–	0.09%	89
2017 Q1	$18K	Hold	550	–	–	0.08%	88
2016 Q4	$20K	Hold	550	–	–	0.1%	86
2016 Q3	$25K	Hold	550	–	–	0.13%	78
2016 Q2	$28K	Hold	550	–	–	0.15%	74
2016 Q1	$29K	Hold	550	–	–	0.16%	72
2015 Q4	$36K	Hold	550	–	–	0.21%	70
2015 Q3	$31K	Hold	550	–	–	0.18%	68
2015 Q2	$33K	Hold	550	–	–	0.21%	67
2015 Q1	$34K	Hold	550	–	–	0.22%	58
2014 Q4	$32K	Hold	550	–	–	0.22%	61
2014 Q3	$30K	Hold	550	–	–	0.23%	58
2014 Q2	$29K	Hold	550	–	–	0.23%	58
2014 Q1	$29K	Hold	550	–	–	0.23%	58
2013 Q4	$22K	Buy	+550	New	+$21.7K	0.22%	65

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SRH Advisors's TEVA Position: Q3 2017 in Review

SRH Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 550 shares — an estimated $18K sold.

SRH Advisors first reported a position in TEVA in Q4 2013 and held it in 15 quarters. The position peaked at $36K in Q4 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

SRH Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
SRH Advisors sold 550 Teva Pharmaceuticals shares in Q3 2017, an estimated $18K.
SRH Advisors first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 15 quarters.
SRH Advisors's Teva Pharmaceuticals position peaked at $36K in Q4 2015.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on SRH Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.